Please disable any ad-blocker you are using in your browser.

Pfizer Inc. (NYSE:PFE) Pill Can Help You In Quitting Smoking


A recent study found that a Pfizer Inc. (NYSE:PFE) pill helped patients quit after cutting back on cigarettes more effectively than smokers who were on a placebo. The drug is sold as Chantix in the U.S. and Champix in the overseas markets. The study scientists advised to revisit practice guidelines to emphasize gradual quitting over immediate cessation.

Lead study author Dr. Jon Ebbert and his colleagues randomly assigned 1,510 smokers across 10 countries to receive either the drug or placebo. This 24-month study was aimed at assessing whether Chantix could help patients quit without quitting abruptly. By the fourth week, investigators asked study participants to cut their cigarette use by 50% and by 75% by week eight. The goal was to ask participants stop smoking by week 12.

During weeks 15 to 24, the group assigned to intervention had significantly higher abstinence rates that the placebo group. Even through weeks 21 through 52, 27% of the people who were assigned to the intervention group avoided smoking, compared with less than 10% of the people who were in the placebo group.

Dr. Ebbert, said the study findings would allow them to target a much broader population of smokers and help them quit without stopping abruptly. The findings also bring strong evidence for changing clinical practices to emphasize gradual reduction.

While this Pfizer Inc. (NYSE:PFE) pill proved effective for some smokers, the intervention group also reported more side effects such as insomnia, nausea, vomiting, constipation and weight gain. According to the World Health Organization, however, tobacco kills one in 10 people globally. Even in the U.S., smoking is the leading cause of preventable death according to the CDC. Quitting can lower the risk of strokes, heart attacks, and cancers of the mouth, bladder, esophagus and throat. As per CDC estimates, the risk of lung cancer decreases by almost 50%, 10 years after quitting.

Lisa Ray

Lisa Ray primarily covers Retail and Healthcare. Lisa Ray has completed her MBA (Finance) and an avid market tracker. She is a stock market analyst who closely tracks US markets along with other global markets like India. She has been expressing her views for years about markets and also advises various clients.

You may also like...

Read previous post:
Actavis Iceland
Win For Astrazeneca Plc (ADR) (NYSE:AZN) And Temporary Injection For Actavis Plc (NYSE:ACT)

Actavis plc (NYSE:ACT) has been prevented from further distribution of generic versions of Pulmicort Respules by the U.S. Court of...

Close